Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency  by Bernspång, Elisabeth et al.
ARTICLE IN PRESS
Respiratory Medicine (2007) 101, 1971–19760954-6111/$ - see fro
doi:10.1016/j.rmed.
Corresponding a
fax: +46 0 40 336225.
E-mail address: eRespiratory symptoms and lung function in 30-year-old
individuals with alpha-1-antitrypsin deﬁciency
Elisabeth Bernspa˚nga,, Tomas Svegerb, Eeva PiitulainenaaDepartment of Respiratory Medicine, Lund University, University Hospital, Malmo¨, Entrance 35, SE-205 02 Malmo¨, Sweden
bDepartment of Clinical Sciences/Paediatrics, Lund University, University Hospital, Malmo¨, SE-205 02 Malmo¨, Sweden
Received 16 January 2007; accepted 5 April 2007






Respiratory symptomnt matter & 2007
2007.04.003
uthor. Tel.: +46 0
lisabeth.bernspanSummary
Introduction: Individuals with severe alpha-1-antitrypsin (AAT) deﬁciency have a well-
known risk of developing emphysema but it is not known at which age the ﬁrst symptoms
occur and lung function declines. The aim of this study was to examine the prevalence of
smoking, respiratory symptoms and lung function at the age of 30 in AAT-deﬁcient
individuals (PiZ and PiSZ) identiﬁed by neonatal screening.
Material and methods: One hundred and seven PiZ, 45 PiSZ and 197 control subjects
(PiMM) ﬁlled in a questionnaire regarding smoking habits and symptoms. Ninety PiZ, 40 PiSZ
and 84 control subjects underwent spirometry including FEV1 and FVC.
Results: Twenty-one percent of PiZ, 23% of PiSZ and 34% of PiMM subjects had smoked at
some time (po0.05). Sixty-ﬁve percent of PiZ, 55% of PiSZ and 35% of PiMM ever-smokers
reported shortness of breath on exertion (po0.05 PiZ vs PiMM). The mean FEV1 was 101%
predicted (95% CI 98–104) in PiZ, 101% predicted (95% CI 97–106) in PiSZ, and 96% predicted
(95% 93–98) in PiMM individuals (po0.05). There was no difference in mean FEV1 when
comparing ever- and neversmokers in the different Pi groups separately.
Conclusion: At the age of 30, the AAT-deﬁcient individuals in this cohort report more
symptoms than the control subjects. Smoking is less common in the cohort compared to
controls. Their lung function is normal.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Severe alpha-1-antitrypsin (AAT) deﬁciency (PiZ) increases
the risk of emphysema, especially in smokers. The
knowledge about when lung function starts to decline isElsevier Ltd. All rights reserved.
40 331000, +46 0 708 827836;
g@med.lu.se (E. Bernspa˚ng).sparse, but most PiZ life-time non-smokers may remain
clinically healthy.1 PiZ individuals also have an increased risk
of liver disease, in children as neonatal cholestasis and in
adults as cirrhosis and hepatocellular carcinoma.2–4 In
moderate deﬁciency (PiSZ) the risk of developing COPD is
also increased but it is not known at which age symptoms
occur and lung function starts to decline.5
The Swedish AAT deﬁciency screening was started in
November 1972 and continued until September 1974 with
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liver disease and to prevent lung disease. During this period,
all Swedish newborn infants, 200 000 children, were
screened for AAT, and those with severe (PiZ), and moderate
(PiSZ) deﬁciency, have been followed every second year
until the age of 18 and since then every fourth year.3,6–8 The
families were advised to stop smoking and/or protect the
child from passive smoking. At 12 years of age and onwards,
the AAT-deﬁcient adolescents were advised not to start
smoking.
The aim of this study was to examine the prevalence of
respiratory symptoms, smoking habits and lung function in
this cohort of AAT-deﬁcient individuals at the age of 30.Methods
Study population
The PiZ and SZ newborn children were identiﬁed by a
neonatal AAT screening method in two steps. First AAT was
measured from dried blood with transferrin as a reference
and the level was determined by electroimmunoassay. If the
serum concentration was less than 40% of the reference the
Pi type was determined by crossed immunoelectrophoresis.3
Screening identiﬁed 127 PiZ, 2 PiZ-, 54 PiSZ and 1 PiS-
subjects. Four PiZ children, who had neonatal liver disease,
died early, but from different causes. Two of them died from
liver cirrhosis and one died from aplastic anaemia, having
liver cirrhosis at autopsy. The fourth one died in an accident.
One PiZ child died from an anaphylactic shock and one PiSZ
child died from a sudden infant death syndrome.
Due to the identiﬁcation of unknown cases born in
1972–1974 there are now 128 PiZ (including two PiZ-) and
55 PiSZ (including one PiS-) individuals in the cohort. All
these individuals were invited to participate in the follow-up
at the age of 30. Since the screening was nationwide, they
lived all over Sweden.
As a control group a random sample of 300 persons living
in the southern part of Sweden (Ska˚ne County) was drawn
from the Swedish Population Registry. The control subjects
were born from January 1973 to September 1974, and thus,
if born in Sweden, had been screened for AAT deﬁciency and
thus not having moderate or severe AAT deﬁciency. The level
of AAT in blood was analysed by immune nephelometry on a
Beckman–Coulter Immage and individuals with decreased
AATwere phenotyped with iso-electric focusing and, if found
to be PiMZ, excluded. All controls with normal levels of AAT
in blood were assumed to be of normal phenotype (PiMM).Table 1 Response frequency, sex ratio and smoking history in
PiZ (n ¼ 107)
Females, n (%) 46 (43)
Smoking habits
Smokers, n (%) 7 (6.5)
Ex-smokers, n (%) 16 (15.0)
Non-smokers, n (%) 84 (78.5)
po0.05 compared to all AAT-deﬁcient subjects.The study was approved by the Regional Ethical Review
Board of Lund University, Sweden. All study participants
gave their signed informed consent.
Questionnaire
A questionnaire, that was a modiﬁed version of the adult
respiratory disease questionnaire used in epidemiological
research,9 was sent to all participants by regular mail. Non-
responding participants were reminded twice by mail and
then rung and interviewed by phone. The questionnaire
included questions regarding smoking habits (age when
starting, age of smoking cessation in ex-smokers, and
average number of cigarettes per day during the time of
smoking), respiratory symptoms (production of phlegm,
wheezing, and shortness of breath when walking on ﬂat
ground) and occupation (including exposure to occupational
dust, fumes or gas). The same questionnaire has been used
at the previous checkups.8,10
Physical examination and dynamic spirometry
The AAT-deﬁcient individuals were invited to undergo
physical examination by a chest physician at their local
hospitals. During the visit, dynamic spirometry, including
FEV1 and FVC, was performed. It was requested that lung
function parameters were to be examined before and 15min
after the administration of inhaled beta2-agonist (Bricanyl
s
1.0mg) and according to ERS guidelines.11 The control
subjects visited the Department of Respiratory Medicine at
the University Hospital, Malmo¨, and performed dynamic
spirometry including FEV1 and FVC, before and 15min after
inhalation of a beta2-agonist (Bricanyl
s 1.0mg). The results
of lung function tests (FEV1 and FVC) are expressed as
percentage of predicted values according to the reference
values of Berglund et al.12 The FEV1/FVC ratio is expressed
as percentage. A positive reversibility test was deﬁned
as 12% and 200ml increase of FEV1 after inhalation of
bronchodilator.
The clinical diagnoses, if any, in the AAT-deﬁcient
individuals were reported by their physician in a survey
protocol, while the control subjects were interviewed by
the study nurse during their clinical visit.
Statistical analysis
Comparison of categorical variables was performed with
the w2 test. For continuous variables the 95% conﬁdencethe three Pi groups.
PiSZ (n ¼ 45) PiMM (n ¼ 197)
22 (49) 106 (54)
5 (11.1) 30 (15.2)
6 (13.3) 36 (18.3)
34 (75.6) 131 (66.5)
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variables were analysed by ANOVA. The p-values were
considered signiﬁcant at the o0.05 level. Statistical
analysis was accomplished using SPSS 12.0.1 software.
Results
Questionnaire
Of the 128 PiZ individuals 107 (84%) completed the







Phlegm 18 (17%) 13 (29%) 31 (16%)
Wheezing 33 (31%) 15 (33%) 41 (21%)
Shortness of
breath
45 (42%) 21 (47%) 77 (39%)
po0.05 compared to PiMM subgroup.
Table 3 Prevalence of symptoms in ever- and never-
smokers in the different Pi groups.
PiZ PiSZ PiMM
Never/ever-smokers, n 84/23 34/11 131/66
Phlegm
Never-smokers 11 (13%) 10 (29%) 14 (11%)
Ever-smokers 7 (30%)z 3 (27%) 17 (26%)J
Wheezing
Never-smokers 22 (26%)y 9 (26%) 19 (15%)
Ever-smokers 11 (48%)z 6 (55%) 22 (33%)J
Shortness of breath
Never-smokers 30 (36%) 15 (44%) 54 (41%)
Ever-smokers 15 (65%)y,z 6 (55%) 23 (35%)
po0.01 compared to PiMM never-smokers.
ypo0.05 compared to corresponding PiMM sub-groups.
zpo0.05 compared to PiZ never-smokers.
Jpo0.001 compared to PiMM never-smokers.
Table 4 Age of study participants and results of lung function
PiZ (n ¼ 90)
Age, years 30.5 (29.2–32.3)
FEV1, % predicted 101 (98–104)
y
FVC, % predicted 100 (97–103)z
FEV1/FVC, % 82 (80–83)
Age is expressed as mean (range) and lung function values as means
po0.001 compared to PiZ+PiSZ.
ypo0.05 compared to PiMM.
zpo0.001 compared to PiMM.
Jpo0.01 compared to PiMM.and 203 (68%) of the 300 control subjects. Six control
subjects, proving to be PiMZ, were excluded from further
analysis. Smoking habits are shown in Table 1. Life-time non-
smokers were signiﬁcantly more common among the AAT-
deﬁcient individuals than among the control subjects
(po0.05). Due to the small numbers of current and ex-
smokers among the AAT-deﬁcient individuals, further com-
parisons were made between ever- and never-smokers.
Tables 2 and 3 demonstrate the prevalence of respiratory
symptoms in the Pi subgroups. The only signiﬁcant difference
between the Pi subgroups as a whole was the increased
prevalence of production of phlegm in the PiSZ subjects when
compared with the PiMM subjects (po0.05). The PiZ ever-
smokers reported a higher prevalence of shortness of breath on
exertion than the PiMM ever-smokers (po0.05) while the PiZ
never-smokers reported a higher prevalence of wheezing than
the PiMM never-smokers (po0.05). All three respiratory
symptoms were more common among the PiZ ever-smokers
than among the PiZ never-smokers. In the PiMM subgroup, the
prevalence of phlegm and wheezing, but not exertional
dyspnoea, were signiﬁcantly increased among the ever-
smokers compared to never-smokers. Among the PiSZ indivi-
duals, no signiﬁcant differences in prevalence of respiratory
symptoms were found between the smokers and non-smokers.
Fifty-seven AAT-deﬁcient subjects (38%) and 59 control
subjects (30%) reported exposure to occupational dust,
fumes or gas. Seventeen (50%) of 34 ever-smoking AAT-
deﬁcient and 25 (38%) of 66 ever-smoking PiMM subjects had
been exposed to occupational dust, fumes or gas. Of these,
11 AAT-deﬁcient subjects (65%) and 8 PiMM subjects (32%)
reported shortness of breath on exertion (po0.05). No
signiﬁcant differences were found in never-smokers.Lung function tests and diagnoses
Spirometry was performed in 90 PiZ, 40 PiSZ and 84 PiMM
individuals. The number of women was 37 (41%), 21 (53%)
and 47 (56%) in each group, respectively. The results of the
lung function tests are shown in Table 4. The control
subjects were somewhat older than the AAT-deﬁcient
individuals (po0.001). The AAT-deﬁcient individuals had
normal lung function, while the mean FEV1 and FVC in the
control subjects were somewhat lower than the expected
values. There were no signiﬁcant differences in the mean
FEV1/FVC ratios between the Pi subgroups.tests.
PiSZ (n ¼ 40) PiMM (n ¼ 84)
30.5 (29.6–32.3) 31.1 (29.8–32.5)
101 (97–106)y 96 (93–98)
101 (97–104)J 93 (91–95)
82 (79–84) 84 (83–85)
(95%CI).
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Table 5 Results of lung function tests in the smoking subgroups.
PiZ PiSZ PiMM
Never/ever-smokers, n 73/17 30/9 52/32
FEV1, % predicted
Never-smokers 100 (97–103) 101 (96–106) 96 (93–98)
Ever-smokers 101 (93–109) 102 (91–112) 96 (92–99)
FVC, % predicted
Never-smokers 99 (96–102) 101 (96–105) 92 (90–95)
Ever-smokers 103 (96–111) 101 (94–109) 94 (91–96)
FEV1/FVC, %
Never-smokers 82 (80–84) 81 (79–84) 84 (83–86)
Ever-smokers 79 (76–83) 82 (75–88) 83 (81–86)
Lung function values are expressed as means (95%CI).
aTwo PiZ and one PiSZ subject did not answer the questionnaire thus not revealing smoking status.
po0.01 compared to PiMM subgroups.
E. Bernspa˚ng et al.1974The results of the lung function tests in the smoking
subgroups are shown in Table 5. The AAT-deﬁcient subgroups
had a larger range in FEV1 and FVC than the control subjects.
However, lung function was normal both in ever- and never-
smoking PiZ and PiSZ individuals. The PiZ ever- and never-
smokers showed a signiﬁcantly higher mean FVC than PiMM
ever- and never-smokers (po0.01), but the FEV1/FVC ratios
did not differ signiﬁcantly between the groups. No differ-
ences were found between ever- and never-smokers within
any of the Pi subgroups. No signiﬁcant differences in lung
function were found between the subjects reporting
exposure to dust, fumes or gas and those unexposed within
any of the Pi subgroups (data not shown).
Sixty-eight PiZ, 32 PiSZ and 84 PiMM subjects performed a
reversibility test and of these, three PiZ (4.4%), four PiSZ
(13%) and ﬁve PiMM (6.0%) had a positive reversibility (n.s.).
A diagnosis of asthma or allergy was reported in 7 of 90
PiZ (7.8%), 5 of 40 PiSZ (11%) individuals and 3 of 84 PiMM
subjects (3.6%) (n.s.). Other diagnoses reported in the PiZ
and PiSZ individuals were colitis (three PiZ individuals),
epilepsy (one PiZ and one PiSZ individual), arthritis (one
PiSZ), depression (one PiZ), herniated disc (one PiSZ),
headache (one PiSZ), panic anxiety syndrome (one PiSZ),
psychosis (one PiZ), rheumatism (one PiSZ) and rosacea (one
PiZ).Drop-outs
Twenty-eight AAT-deﬁcient individuals (15%) did not partici-
pate in the survey. Five refused any participation, 18 did not
answer letters nor phone calls, three were not registered at
a known address, one could not participate due to serious
mental illness and one living abroad had no possibility of
participating. Three underwent the clinical examination but
did not ﬁll in the questionnaire and 25 answered the
questions but did not undergo the physical examination or
perform spirometry. Their reasons for not seeing their
doctor were lack of time or no interest; one expressed fear
of detecting disease.
Thirty-seven control subjects (12%) refused all participa-
tion and 111 (37%) completed the questionnaire but refused
lung function testing in hospital. Lack of time was the mostcommon reason not to participate. Other reasons were no
interest, handicap, difﬁculty in understanding Swedish and
moving out of the area. Sixty control subjects (20%) did not
answer letters nor phone calls.Discussion
At 30 years of age these AAT-deﬁcient individuals still have
normal lung function. Smoking is less common among the
AAT-deﬁcient individuals than the control subjects indicating
successful anti-tobacco information to the cohort.
As a whole, the AAT-deﬁcient individuals had more
symptoms than the control subjects but the difference was
signiﬁcant only in prevalence of phlegm between the PiSZ
and PiMM subjects (Table 2). Among the smokers, the PiZ
individuals had signiﬁcantly higher prevalence of shortness
of breath than the PiMM smokers which may indicate that
they are more vulnerable to disease (Table 3), dyspnoea on
exertion being a classic early symptom of emphysema.13,14
The PiZ ever-smokers, like the PiMM ever-smokers, also had
a signiﬁcantly increased prevalence of phlegm and wheezing
than the never-smokers in the same Pi subgroup. Already at
the age of 22 PiZ ever-smokers reported a higher prevalence
of wheezing than PiZ never-smokers.10 No differences were
found between the PiSZ and PiMM smokers. The number of
smoking PiSZ individuals was small but our results may
indicate that PiSZ smokers develop respiratory symptoms
later than PiZ smokers. The risk of COPD in individuals with
moderate AAT deﬁciency (PiSZ) is considered lower than in
those with severe deﬁciency (PiZ), but not in any way
negligible. In a meta-analysis Dahl et al.15 showed a three
times greater risk for COPD in PiSZ individuals compared to
PiMM controls. Another study has shown that PiSZ individuals
have a risk of developing emphysema but later than in those
with the PiZ phenotype.5
Although we found increased prevalence of symptoms in
the PiZ and PiMM smokers versus non-smokers, no signiﬁcant
differences in lung function were found between smokers
and non-smokers in any Pi group. At 18 years of age, FEV1/
FVC ratio in AAT-deﬁcient adolescents was slightly decreased
compared to controls. Ever-smoking AAT-deﬁcient indivi-
duals had lower FEV1 and FEV1/FVC ratio in comparison with
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and 26, lung function was normal in the PiZ and PiSZ
individuals.8,10 In the present study, at the age of 30, both
smokers and non-smokers still have normal lung function
when considering sex, age and length and also compared to
an age-matched control group drawn from the general
population.
A limitation of this study is the fact that the AAT-deﬁcient
subjects have been informed about their risk of pulmonary
disease and therefore may be more prone to report
respiratory symptoms than the control subjects. On the
other hand did several controls subjects report respiratory
symptoms. Even if the lower lung function values in this
group could be due to a systemic measurement failure since
all control subjects were examined at the same location, it
is more likely that this unintended selection of particularly
symptomatic control subjects also have lower lung function,
a relation that has been shown in previous studies.16,17
Another factor that may inﬂuence the test results are that
the AAT-deﬁcient individuals are used to perform spirome-
try, thus further contributing to the difference in lung
function between AAT-deﬁcient and control individuals.
To our knowledge, this is the only cohort of AAT-deﬁcient
young adults that has been followed for as long as 30 years,
which is why there are few possibilities to compare with
other groups. Results based on data from the Danish AAT
Deﬁciency Registry have shown smoking PiZ individuals older
than 25 years, to have a steeper decline in FEV1 than PiZ
non-smokers.18 Analysis of data from the Swedish AAT
registry has shown that never-smoking PiZ individuals have
in average normal lung function up to the age of 50.19 In
another study on PiZ individuals included in the Swedish AAT
Registry current smokers showed a steeper decline in FEV1
than ex-smokers and non-smokers.20 In a general popula-
tion, the European Community Respiratory Health Survey
(ECRHS-I) shows that in individuals between 20 and 44 years
of age, smoking causes lower lung function.21 We did not
ﬁnd such results in AAT-deﬁcient individuals at the age of 30.
A randomised control group from the general population
was selected for this study to achieve higher accuracy of the
results than at previous checkups. At the 26 year-old
checkup the relatively small control group comprised nurses
and medical school students, all non-smokers. At the
present checkup, a randomly selected group of 300
individuals were drawn from the Swedish population
registry. The controls lived in the Ska˚ne County where the
University hospital, Malmo¨, is located. This county is one of
the top ﬁve Swedish counties regarding prevalence of
smoking,22 which may have contributed to the difference
in smoking habits between AAT-deﬁcient individuals and
controls.
Difﬁculty in making contact with the controls postponed
their examination and largely explains the small difference
in age between AAT-deﬁcient individuals and controls.
In the present study, the participation rate among the
AAT-deﬁcient individuals was higher than at the previous
checkups. At 26 years of age, 73%the questionnaire and 65%
underwent physical examination and spirometry.8 At 30
years of age, 83% completed the questionnaire and 71%
underwent physical examination and spirometry. Becoming a
parent increases health concerns and when these AAT-
deﬁcient individuals now have their own children they mightbe more prone to participate. A question frequently asked
was how to detect a possible deﬁciency in their infants.
While the AAT-deﬁcient individuals had a better response
frequency than at previous checkups, it was hard to get the
controls to participate. This has been reported previously
both for the general population in the south of Sweden23 and
for young, smoking men in the north of Sweden.24 If this is an
increasing problem, future surveys will face problems when
there are difﬁculties in recruiting study participants, leading
to less accurate results.
In conclusion, at the age of 30 years, AAT-deﬁcient
individuals smoke less than age-matched control subjects.
The PiZ smokers report higher prevalence of respiratory
symptoms which may indicate an early sign of emphysema.
All PiZ and SZ individuals still have normal lung function.Conﬂict of interest statement
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